Although high concentrations of IL-6 in GVHD patients indicate poor prognoses, the immunomodulatory effects of DSCs can be activated by IL-6 signaling, suggesting that DSCs may serve as a promising cell therapy for GVHD. Here, IL6 is linked to graft versus host disease.